Results 21 to 30 of about 284,282 (314)

COVID-19 in Immunocompromised Hosts: What We Know So Far

Clinical Infectious Diseases, 2020
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide.
M. Fung, Jennifer M Babik
semanticscholar   +1 more source

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

medRxiv, 2021
Background: Patients with immunocompromised disorders have mainly been excluded from clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial was to investigate the safety and efficacy after two doses of BNT162b2 ...
P. Bergman, O. Blennow, L. Hansson, Stephanie Mielke, Piotr Nowak, Puran Chen, G. Söderdahl, A. Österborg, C. E. Edvard Smith, David Wullimann, J. Vesterbacka, Gustaf Lindgren, Lisa Blixt, G. Friman, Emilie Wahren-Borgström, A. Nordlander, Angela C. Gomez, Mira Akber, D. Valentini, A. Norlin, A. Thalme, G. Bogdanovic, S. Muschiol, P. Nilsson, S. Hober, K. Loré, M. Chen, M. Buggert, H. Ljunggren, P. Ljungman, S. Aleman   +30 more
semanticscholar   +1 more source

Infections in the Immunocompromised [PDF]

, 2009
Infections in the immunocompromised differ significantly from those in the immunocompetent. They can be more serious, more often life threatening, more difficult to diagnose and are caused by more unusual organisms. Children can be immunocompromised for a variety of reasons and the numbers, worldwide, are growing.
Cant, Andrew, Cole, Theresa
openaire   +2 more sources

Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial

Infection, 2023
Purpose Immunocompromised patients have a potentially increased risk for progression to severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis examined outcomes among immunocompromised participants in the MOVe-OUT trial.
Matthew G. Johnson, J. Strizki, M. Brown, H. Wan, H. Shamsuddin, M. Ramgopal, D. Florescu, P. Delobel, I. Khaertynova, J. Flores, Leon F Fouche, Shan-Chwen Chang, A. Williams-Diaz, Jiejun Du, J. Grobler, Amanda Paschke, Carisa De Anda   +16 more
semanticscholar   +1 more source

Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host

Nature Communications, 2022
Different scenarios explaining the emergence of novel variants of concern (VOC) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported, including their evolution in scarcely monitored populations, in animals as alternative
S. Sonnleitner, M. Prelog, S. Sonnleitner, E. Hinterbichler, H. Halbfurter, D. B. Kopecky, G. Almanzar, Stephan Koblmüller, C. Sturmbauer, L. Feist, R. Horres, W. Posch, G. Walder   +12 more
semanticscholar   +1 more source

Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan

Viruses, 2023
The coronavirus disease (COVID-19) pandemic continues to threaten global public health. Remdesivir and monoclonal antibodies have shown promise for COVID-19 treatment of patients who are immunocompromised, including those with cancer, transplant ...
Jun Hirai, Nobuaki Mori, Daisuke Sakanashi, Wataru Ohashi, Yuichi Shibata, Nobuhiro Asai, Hideo Kato, Mao Hagihara, Hiroshige Mikamo   +8 more
doaj   +1 more source

Immunocompromised travellers

International Maritime Health, 2017
Given a better quality of life and extended life expectancy in patients with immune suppression, the number of immunocompromised travellers is constantly growing. The aim of the article is to discuss travel-related health problems in immunocompromised patients, their most common destinations and reasons to travel, as well as complications associated ...
Katarzyna, Wasilczuk, Krzysztof, Korzeniewski   +1 more
openaire   +3 more sources

Talaromyces amestolkiae Infection in an AIDS Patient with Cryptococcal Meningitis

Journal of Fungi, 2023
Concurrent infections caused by multiple fungal pathogens in immunocompromised patients can pose diagnostic and treatment challenges. Here, we presented the first reported case in Taiwan of an AIDS patient who had concurrent infection with Cryptococcus ...
Li-An Wang, Yu-Chuan Chuang, Ting-Kuang Yeh, Kuan-Pei Lin, Chi-Jan Lin, Po-Yu Liu   +5 more
doaj   +1 more source

Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: the EPOCH-US Study

Current Medical Research and Opinion, 2023
Objective To estimate the prevalence of patients with an immunocompromising condition at risk for COVID-19, estimate COVID-19 prevalence rate (PR) and incidence rate (IR) by immunocompromising condition, and describe COVID-19-related healthcare resource ...
Amita Ketkar, V. Willey, M. Pollack, Lisa I Glasser, C. Dobie, Cachet M. Wenziger, C. Teng, C. Dube, Dennis Cunningham, Monica Verduzco-Gutierrez   +9 more
semanticscholar   +1 more source

A Review on the Impact of the SARS-CoV-2 Omicron Subvariant on Elderly Patients with Diverse Co-Morbidities

Biologics, 2023
The SARS-CoV-2 virus has caused a catastrophic impact on the world for the past 3 years. The virus has now returned with the emergence of the Omicron (B.1.1.529) variant.
Avinash Khadela, Shruti Soni, Kaivalya Megha, Shivam Bhagat, Vivek P. Chavda   +4 more
doaj   +1 more source